NeuMedics was founded in Washington State in 2008.  It is a development stage biopharmaceutical company focused on the rapid development of therapies to treat Diabetic Macular Edema (DME) and related inflammatory conditions.

Neumedics lead compound NM108

  • is a proprietary compound.
  • is non-steroidal,
  • non-mAb
  • eye drop
  • a novel mechanism-of-action
  • and can be self-administered by patients.